 Dong Miao
Concepts (209)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Autoantibodies | 32 | 2022 | 1512 | 1.830 |
Why?
| | Glutamate Decarboxylase | 10 | 2022 | 165 | 1.090 |
Why?
| | Diabetes Mellitus, Type 1 | 32 | 2022 | 3917 | 1.060 |
Why?
| | Insulin Antibodies | 10 | 2016 | 103 | 0.920 |
Why?
| | Prediabetic State | 6 | 2015 | 247 | 0.860 |
Why?
| | Luminescence | 4 | 2016 | 38 | 0.680 |
Why?
| | Celiac Disease | 8 | 2022 | 310 | 0.610 |
Why?
| | Luminescent Measurements | 6 | 2021 | 76 | 0.590 |
Why?
| | Apolipoprotein A-I | 1 | 2016 | 39 | 0.470 |
Why?
| | Cardiomegaly | 1 | 2016 | 174 | 0.430 |
Why?
| | Cholesterol | 1 | 2016 | 405 | 0.410 |
Why?
| | Islets of Langerhans | 12 | 2019 | 846 | 0.390 |
Why?
| | Transglutaminases | 5 | 2016 | 159 | 0.360 |
Why?
| | Lipoproteins, HDL | 1 | 2011 | 99 | 0.330 |
Why?
| | Sensitivity and Specificity | 12 | 2022 | 2002 | 0.320 |
Why?
| | Hyperlipidemias | 1 | 2011 | 120 | 0.320 |
Why?
| | Carotid Arteries | 1 | 2011 | 208 | 0.310 |
Why?
| | Insulin | 14 | 2016 | 2506 | 0.310 |
Why?
| | Proinsulin | 5 | 2013 | 52 | 0.300 |
Why?
| | Electrochemical Techniques | 2 | 2020 | 55 | 0.290 |
Why?
| | Mass Screening | 6 | 2021 | 1358 | 0.290 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2011 | 394 | 0.270 |
Why?
| | Peptide Fragments | 7 | 2004 | 693 | 0.260 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 4 | 2016 | 54 | 0.250 |
Why?
| | Vascular Stiffness | 1 | 2011 | 486 | 0.240 |
Why?
| | Autoantigens | 3 | 2009 | 426 | 0.220 |
Why?
| | Zinc Transporter 8 | 3 | 2021 | 70 | 0.220 |
Why?
| | Epitopes | 2 | 2005 | 480 | 0.200 |
Why?
| | Hypertension | 1 | 2011 | 1273 | 0.180 |
Why?
| | Protein Tyrosine Phosphatases | 2 | 2004 | 167 | 0.170 |
Why?
| | Triglycerides | 2 | 2016 | 518 | 0.170 |
Why?
| | Predictive Value of Tests | 6 | 2015 | 2129 | 0.170 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 253 | 0.170 |
Why?
| | Poly I-C | 3 | 2005 | 58 | 0.150 |
Why?
| | Health Fairs | 1 | 2019 | 10 | 0.150 |
Why?
| | Biomarkers | 5 | 2022 | 4283 | 0.150 |
Why?
| | Genotype | 5 | 2015 | 1853 | 0.140 |
Why?
| | High-Throughput Screening Assays | 1 | 2019 | 177 | 0.130 |
Why?
| | Steroid 21-Hydroxylase | 2 | 2009 | 27 | 0.130 |
Why?
| | Addison Disease | 2 | 2009 | 38 | 0.130 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2022 | 2582 | 0.130 |
Why?
| | Child, Preschool | 13 | 2019 | 11837 | 0.130 |
Why?
| | China | 2 | 2021 | 271 | 0.120 |
Why?
| | ATP Binding Cassette Transporter 1 | 1 | 2016 | 13 | 0.120 |
Why?
| | Autoimmune Diseases | 2 | 2019 | 469 | 0.120 |
Why?
| | Liver X Receptors | 1 | 2016 | 29 | 0.120 |
Why?
| | Disease Progression | 6 | 2016 | 2862 | 0.120 |
Why?
| | Child | 15 | 2022 | 22680 | 0.110 |
Why?
| | Female | 22 | 2021 | 78763 | 0.110 |
Why?
| | Diet, Western | 1 | 2016 | 88 | 0.110 |
Why?
| | Infant | 10 | 2019 | 10064 | 0.110 |
Why?
| | Membrane Proteins | 1 | 2002 | 1164 | 0.110 |
Why?
| | Hypercholesterolemia | 1 | 2016 | 95 | 0.110 |
Why?
| | Mice, Knockout | 6 | 2016 | 3125 | 0.110 |
Why?
| | Protein Precursors | 3 | 2004 | 136 | 0.110 |
Why?
| | Biological Transport | 1 | 2016 | 422 | 0.110 |
Why?
| | Cholesterol, LDL | 1 | 2016 | 359 | 0.100 |
Why?
| | Risk Factors | 9 | 2021 | 10874 | 0.100 |
Why?
| | Mice, Inbred NOD | 9 | 2005 | 613 | 0.100 |
Why?
| | Humans | 29 | 2022 | 145491 | 0.100 |
Why?
| | Autoimmunity | 4 | 2016 | 936 | 0.100 |
Why?
| | Radioimmunoassay | 4 | 2016 | 165 | 0.090 |
Why?
| | Male | 16 | 2021 | 72817 | 0.090 |
Why?
| | Cation Transport Proteins | 2 | 2013 | 118 | 0.090 |
Why?
| | Diabetes Mellitus, Experimental | 2 | 2005 | 185 | 0.090 |
Why?
| | Polymorphism, Genetic | 3 | 2009 | 616 | 0.090 |
Why?
| | Mice | 15 | 2016 | 18338 | 0.090 |
Why?
| | Adolescent | 11 | 2019 | 22485 | 0.090 |
Why?
| | Diastole | 1 | 2011 | 146 | 0.080 |
Why?
| | Risk | 1 | 2013 | 917 | 0.080 |
Why?
| | Histocompatibility Antigens Class I | 2 | 2009 | 203 | 0.080 |
Why?
| | Incidence | 2 | 2021 | 2915 | 0.080 |
Why?
| | Health Surveys | 1 | 2011 | 518 | 0.070 |
Why?
| | Interferon-alpha | 2 | 2009 | 194 | 0.070 |
Why?
| | Laboratories | 1 | 2009 | 110 | 0.070 |
Why?
| | Mice, Inbred BALB C | 6 | 2005 | 1261 | 0.060 |
Why?
| | Animals | 15 | 2016 | 38141 | 0.060 |
Why?
| | Diagnostic Techniques, Endocrine | 2 | 2019 | 14 | 0.060 |
Why?
| | CD4 Antigens | 2 | 2003 | 137 | 0.060 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 2 | 2004 | 44 | 0.060 |
Why?
| | Edible Grain | 1 | 2005 | 48 | 0.060 |
Why?
| | Glutens | 1 | 2005 | 60 | 0.050 |
Why?
| | Transgenes | 1 | 2004 | 191 | 0.050 |
Why?
| | Follow-Up Studies | 4 | 2021 | 5426 | 0.050 |
Why?
| | Immunity, Mucosal | 1 | 2004 | 98 | 0.050 |
Why?
| | Alanine | 1 | 2004 | 170 | 0.050 |
Why?
| | Genetic Testing | 1 | 2005 | 480 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2011 | 839 | 0.050 |
Why?
| | Osteopontin | 1 | 2022 | 35 | 0.050 |
Why?
| | Young Adult | 5 | 2019 | 14192 | 0.040 |
Why?
| | Animals, Newborn | 1 | 2004 | 890 | 0.040 |
Why?
| | HLA-DQ Antigens | 3 | 2009 | 174 | 0.040 |
Why?
| | Adult | 7 | 2021 | 40707 | 0.040 |
Why?
| | Middle Aged | 5 | 2021 | 36176 | 0.040 |
Why?
| | Models, Immunological | 1 | 2002 | 100 | 0.040 |
Why?
| | Electrochemistry | 1 | 2021 | 72 | 0.040 |
Why?
| | Fetal Blood | 1 | 2004 | 325 | 0.040 |
Why?
| | Prospective Studies | 5 | 2016 | 8039 | 0.040 |
Why?
| | Anaphylaxis | 1 | 2002 | 102 | 0.040 |
Why?
| | Phenotype | 3 | 2021 | 3157 | 0.040 |
Why?
| | Mice, Transgenic | 4 | 2005 | 2189 | 0.040 |
Why?
| | Injections, Subcutaneous | 3 | 2004 | 170 | 0.040 |
Why?
| | Blood Specimen Collection | 1 | 2019 | 37 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2020 | 343 | 0.040 |
Why?
| | Cardiovascular Diseases | 1 | 2011 | 2185 | 0.040 |
Why?
| | Risk Assessment | 2 | 2020 | 3759 | 0.040 |
Why?
| | Antibody Specificity | 2 | 2011 | 178 | 0.040 |
Why?
| | Biopsy | 2 | 2016 | 1081 | 0.030 |
Why?
| | Aged | 3 | 2021 | 26125 | 0.030 |
Why?
| | Proportional Hazards Models | 2 | 2016 | 1332 | 0.030 |
Why?
| | Community Health Services | 1 | 2019 | 231 | 0.030 |
Why?
| | Diet | 1 | 2005 | 1280 | 0.030 |
Why?
| | Population Surveillance | 1 | 2020 | 485 | 0.030 |
Why?
| | Homozygote | 2 | 2009 | 200 | 0.030 |
Why?
| | HLA-DR Antigens | 2 | 2009 | 220 | 0.030 |
Why?
| | Time Factors | 4 | 2016 | 7171 | 0.030 |
Why?
| | Prognosis | 2 | 2021 | 4323 | 0.030 |
Why?
| | Disease Management | 1 | 2020 | 654 | 0.030 |
Why?
| | Age of Onset | 2 | 2011 | 554 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2003 | 1511 | 0.030 |
Why?
| | Peptides | 1 | 2002 | 993 | 0.030 |
Why?
| | Antibody Affinity | 1 | 2016 | 60 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2022 | 1378 | 0.030 |
Why?
| | Transcription Factors | 1 | 2003 | 1733 | 0.030 |
Why?
| | Proteomics | 1 | 2022 | 1191 | 0.030 |
Why?
| | C-Peptide | 1 | 2016 | 190 | 0.030 |
Why?
| | Blood Glucose | 3 | 2016 | 2330 | 0.030 |
Why?
| | Cohort Studies | 2 | 2021 | 5992 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 700 | 0.030 |
Why?
| | Adoptive Transfer | 2 | 2005 | 199 | 0.030 |
Why?
| | Mice, SCID | 2 | 2005 | 369 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2005 | 1138 | 0.020 |
Why?
| | Alleles | 2 | 2009 | 893 | 0.020 |
Why?
| | Case-Control Studies | 2 | 2011 | 3619 | 0.020 |
Why?
| | Mice, Inbred C57BL | 4 | 2005 | 5989 | 0.020 |
Why?
| | Spleen | 2 | 2005 | 511 | 0.020 |
Why?
| | Administration, Oral | 2 | 2004 | 863 | 0.020 |
Why?
| | Iodine Radioisotopes | 1 | 2011 | 137 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3424 | 0.020 |
Why?
| | HLA-DQ beta-Chains | 1 | 2009 | 58 | 0.020 |
Why?
| | Graves Disease | 1 | 2009 | 32 | 0.020 |
Why?
| | Colorado | 1 | 2019 | 4572 | 0.020 |
Why?
| | Radioligand Assay | 1 | 2009 | 36 | 0.020 |
Why?
| | HLA-DRB1 Chains | 1 | 2009 | 110 | 0.020 |
Why?
| | Microsatellite Repeats | 1 | 2009 | 156 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2016 | 2950 | 0.020 |
Why?
| | Infant, Newborn | 3 | 2005 | 6437 | 0.020 |
Why?
| | International Cooperation | 1 | 2009 | 197 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2011 | 1507 | 0.020 |
Why?
| | Recombinant Fusion Proteins | 1 | 2009 | 667 | 0.020 |
Why?
| | ROC Curve | 1 | 2009 | 619 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 1049 | 0.020 |
Why?
| | T-Lymphocytes | 2 | 2004 | 1996 | 0.010 |
Why?
| | Thyroglobulin | 1 | 2005 | 29 | 0.010 |
Why?
| | Iodide Peroxidase | 1 | 2005 | 35 | 0.010 |
Why?
| | Integrin alpha Chains | 1 | 2004 | 22 | 0.010 |
Why?
| | Ovum | 1 | 2004 | 31 | 0.010 |
Why?
| | Microinjections | 1 | 2004 | 92 | 0.010 |
Why?
| | Crosses, Genetic | 1 | 2004 | 125 | 0.010 |
Why?
| | Family Health | 1 | 2005 | 191 | 0.010 |
Why?
| | Histocompatibility Testing | 1 | 2004 | 123 | 0.010 |
Why?
| | HLA-DR4 Antigen | 1 | 2004 | 74 | 0.010 |
Why?
| | Organ Specificity | 1 | 2005 | 312 | 0.010 |
Why?
| | HLA-DR3 Antigen | 1 | 2004 | 76 | 0.010 |
Why?
| | B7-1 Antigen | 1 | 2004 | 55 | 0.010 |
Why?
| | False Positive Reactions | 1 | 2004 | 123 | 0.010 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2004 | 147 | 0.010 |
Why?
| | Models, Biological | 1 | 2011 | 1815 | 0.010 |
Why?
| | Intestine, Small | 1 | 2005 | 167 | 0.010 |
Why?
| | Heterozygote | 1 | 2004 | 313 | 0.010 |
Why?
| | Amino Acid Substitution | 1 | 2004 | 303 | 0.010 |
Why?
| | Maternal-Fetal Exchange | 1 | 2004 | 170 | 0.010 |
Why?
| | HLA Antigens | 1 | 2005 | 238 | 0.010 |
Why?
| | Single-Blind Method | 1 | 2004 | 319 | 0.010 |
Why?
| | Isoenzymes | 1 | 2004 | 297 | 0.010 |
Why?
| | Cyclophosphamide | 1 | 2003 | 266 | 0.010 |
Why?
| | T-Box Domain Proteins | 1 | 2003 | 106 | 0.010 |
Why?
| | Species Specificity | 1 | 2004 | 573 | 0.010 |
Why?
| | Enkephalins | 1 | 2002 | 21 | 0.010 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2003 | 70 | 0.010 |
Why?
| | Delivery, Obstetric | 1 | 2004 | 161 | 0.010 |
Why?
| | DNA Primers | 1 | 2003 | 507 | 0.010 |
Why?
| | Pyridinium Compounds | 1 | 2002 | 31 | 0.010 |
Why?
| | Hydrocortisone | 1 | 2004 | 298 | 0.010 |
Why?
| | CD8 Antigens | 1 | 2002 | 70 | 0.010 |
Why?
| | Antigens, CD | 1 | 2004 | 557 | 0.010 |
Why?
| | Regression Analysis | 1 | 2004 | 1001 | 0.010 |
Why?
| | Antibodies | 1 | 2003 | 398 | 0.010 |
Why?
| | Glucagon | 1 | 2002 | 114 | 0.010 |
Why?
| | Pregnancy | 2 | 2004 | 7197 | 0.010 |
Why?
| | Immunoglobulin E | 1 | 2002 | 315 | 0.010 |
Why?
| | Immunization | 1 | 2002 | 375 | 0.010 |
Why?
| | Adjuvants, Immunologic | 1 | 2002 | 246 | 0.010 |
Why?
| | Gene Expression | 1 | 2005 | 1478 | 0.010 |
Why?
| | Survival Analysis | 1 | 2003 | 1374 | 0.010 |
Why?
| | Base Sequence | 1 | 2003 | 2180 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2004 | 1247 | 0.010 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2005 | 917 | 0.010 |
Why?
| | Proteins | 1 | 2004 | 1020 | 0.010 |
Why?
| | Immunoglobulin G | 1 | 2002 | 890 | 0.010 |
Why?
| | Immunity, Innate | 1 | 2004 | 846 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2002 | 1710 | 0.010 |
Why?
| | Prevalence | 1 | 2005 | 2855 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2009 | 5891 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2002 | 2030 | 0.010 |
Why?
| | Rats | 1 | 2004 | 5581 | 0.010 |
Why?
| | Vaccination | 1 | 2003 | 1423 | 0.010 |
Why?
| | Aging | 1 | 2005 | 1940 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2004 | 4559 | 0.010 |
Why?
|
|
Miao's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|